EU/3/10/846 : Orphan designation for the treatment of oesophagus carcinoma
Table of contents
On 23 February 2011, orphan designation (EU/3/10/846) was granted by the European Commission to BTG plc, United Kingdom, for paclitaxel (aqueous gel) for the treatment of oesophagus carcinoma.
Treatment of oesophagus carcinoma
|Orphan designation status||
|EU designation number||
|Date of designation||
5 Fleet Place
London EC4M 7RD
Tel. + 44 (0)20 7575 0000
Fax + 44 (0)20 7575 0010
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: